“Newron reported 2025 as a landmark year, driven by progress in its Evenamide program, including regulatory approval and initiation of the pivotal ENIGMA-TRS phase III trials in treatment-resistant schizophrenia across multiple regions. Partner EA Pharma launched a phase III trial in Japan, while Newron secured an additional European composition-of-matter patent for Evenamide extending exclusivity to 2044.
The company strengthened its scientific and market profile through multiple peer-reviewed publications and conference presentations supporting Evenamide’s novel mechanism and broad symptom coverage in schizophrenia. Corporate developments included a new board chairman, planned refresh of independent directors, expanded analyst coverage, and up to EUR 38 million in new equity plus extended EIB debt maturities, collectively bolstering its cash runway to advance phase III trials and prepare for potential marketing and listing initiatives.”